Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.50 |
| ▸ | GABRE | P78334 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952809 | 1.00 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL70537 | 0.81 | HCAR2 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30937742 | 0.80 | SMN1; SMN2 (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29804459 | 0.78 | SIRT3 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13270684 | 0.76 | SIRT3 (0.31) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13164028 | 0.75 | TSHR (0.44) | KDM4EHPGDHSD17B10ALDH1A1KMT2A | |
| SCHEMBL30986544 | 0.75 | MEN1 (0.37) | KDM4EHPGDALDH1A1KMT2A | |
| SCHEMBL14076466 | 0.74 | AKR1C3 (0.48) | KDM4EALDH1A1KMT2AGAACYP1A2 | |
| SCHEMBL31021653 | 0.73 | P2RX7 (0.46) | KDM4EALDH1A1KMT2AGAACYP1A2 | |
| SCHEMBL28302666 | 0.73 | NNMT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2026-04-09 | — | — | US | disclosed |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-11-04 | — | — | US | disclosed |
| EP-4311577-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Ji Xing Pharmaceuticals Hong Kong Limited (HK) | 2024-01-31 | — | — | EP | disclosed |
| EP-3562487-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-11-29 | — | — | EP | disclosed |
| EP-3562487-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-11-29 | — | — | EP | disclosed |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2021-10-21 | — | — | US | disclosed |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2021-10-21 | — | — | US | disclosed |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CYP11B2, CYP11B1, HSD11B2 | GABRP 3680/4885GABRD 2638/4885GABRA1 2982/4885 |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | GABRP 2246/4885GABRD 2713/4885GABRA1 3438/4885 |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CPN1, TPP1, DPP4 | GABRP 1154/4885GABRD 2083/4885GABRA1 2216/4885 |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | GABRP 3818/4885GABRD 3589/4885GABRA1 4442/4885 |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | GABRP 3818/4885GABRD 3589/4885GABRA1 4442/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | GABRP 438/4885GABRD 1126/4885GABRA1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.